NXTC +220% premarket; Nextcure and avere Therapeutics announce merger to advance once-weekly oral il-23 therapy Nextcure - combined company
NXTC +220% premarket; Nextcure and avere Therapeutics announce merger to advance once-weekly oral il-23 therapy Nextcure - combined company to operate as avere Therapeutics, trade as avrx after merger in h2 2026 - And avere Therapeutics announce definitive all-stock merger agreement - Announces concurrent $320M private